In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

British pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, consists of over 4.3 billion ordinary shares, with a total ...

GSK have sensibly IMV taken the whole hit in this quarter and all else equal will still return an OP of £ 5 billion for this FY. Anyone who reads my posts will know that I am not a fan of ...